RET and non-small cell lung carcinoma: With praseltinib being a highly effective treatment (an ORR of 70%, an mDOR not reached after 6 months, and the presence of CR in some cases), the ARROW trial [112] led to the approval of praseltinib in the first-line setting of RET-rearranged NSCLC.